Virus-armed immune cells take on tough melanoma in early trial
NCT ID NCT06961786
First seen Mar 19, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early-stage study tests a new approach for people with advanced melanoma that has not responded to standard treatments. Nine participants will receive a special virus (TILT-123) designed to boost the immune system, along with chemotherapy and their own lab-grown immune cells (TILs). The main goal is to check safety and see if the combination can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Center for Cancer Immune Therapy Herlev Hospital, Copenhagen University
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.